Post Content
Canada’s Drug Agency (CDA-AMC) recommends that Itovebi in combination with palbociclib (PAL) and fulvestrant (FUL) be reimbursed by public drug
Early relationships are foundational for lifelong health, learning, and well-being. Mutual, meaningful, and affirming moments of connection in the youngest
Recent reports based on the US Food and Drug Administration’s voluntary Adverse Events Reporting System raised questions about the safety
The Formulary Management Expert Committee (FMEC) recommends that pertuzumab in combination with trastuzumab and chemotherapy be reimbursed for the treatment
Chiari type I malformation (CM) and syringomyelia (SM) are closely associated but incompletely understood disorders of the craniovertebral junction and
Chronic pain is common and often undertreated. Access to effective, nonpharmacologic therapies is limited, especially in low-income and ethnically diverse
Canada’s Drug Agency (CDA-AMC) recommends that Nubeqa be reimbursed by public drug plans for use in combination with androgen deprivation
Registration No: 771800548 Contact Number : +91-8249516996
